Dr. Brian H. Buck, MD, FRCPC
Claim this profileUniversity of Alberta
Studies Stroke
Studies Bleeding
11 reported clinical trials
18 drugs studied
Affiliated Hospitals
Clinical Trials Brian H. Buck, MD, FRCPC is currently running
Tenecteplase
for Stroke
This domain has a prospective, randomized, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design. Up to 4,000 patients with presumed acute ischemic stroke (AIS) will be followed for 90 days (or until death, if prior to 90 days). The end of the trial is defined as the date that all participants have completed their Day 90 assessment. This domain aim is to efficiently, reliably, and simultaneously, determine the comparative effectiveness of intravenous thrombolysis (IVT) using standard-dose intravenous tenecteplase (0.25 mg/kg body weight), vs. low-dose intravenous tenecteplase (0.18 mg/kg body weight) in all patients who present to hospital with acute ischemic stroke and are considered for intravenous thrombolysis. In addition, this domain also seeks to study standard-dose intravenous tenecteplase (0.25 mg/kg body weight), vs. low-dose intravenous tenecteplase (0.18 mg/kg body weight) vs. no TNK upfront with rescue IA TNK if necessary (in those eligible for emergency EVT) and no TNK upfront in those who have taken DOACs during the preceding 24 hours. This domain therefore seeks to generate more robust randomized evidence to guide clinicians in their decisions over the balance of risks and treatment with intravenous thrombolysis with tenecteplase wherever such evidence is currently insufficient. This domain will currently evaluate four research questions in relation to the use of IVT with tenecteplase: 1. In patients with recent (24 hours) intake of a standard-dose direct oral anticoagulant (DOAC), how should IVT be used? - Use standard-dose (0.25 mg/kg body weight) or low-dose tenecteplase (0.18 mg/kg) or not at all. 2. In patients planned to be treated with endovascular thrombectomy, how should tenecteplase be used? -Treat with IV tenecteplase (standard- or low-dose) or not at all. 3. In any patient receiving IVT, what is the optimal dose of tenecteplase? - use standard-dose (0.25 mg/kg body weight) or low-dose tenecteplase (0.18 mg/kg). 4. To what extent is the treatment effect of standard- vs. low-dose tenecteplase modified by key patient characteristics, such as diabetes, prior antiplatelet therapy, renal failure, or frailty, old age or having a heavy burden of cerebral small vessel disease on brain imaging.
Recruiting2 awards Phase 3
Guided Stepping Training
for Stroke Recovery
Goal of research program: To understand person-specific factors, such as imaging markers and activity patterns early after stroke, that may guide precision rehabilitation to optimize function and improve recovery. Objectives: 1. Test the effect of reducing sedentary behaviour early after stroke on functional mobility and global disability outcomes. 2. Determine the impact of neuroimaging biomarkers (e.g. leukoaraiosis) on response to rehabilitation. 3. Explore the predictive value of accelerometry as an adjunct to the subjective modified Rankin Scale (mRS) to assess functional disability after stroke. Experimental approach/Research Plan/Use of Funds: The investigators aim to recruit 50 participants within 1 week of ischemic stroke onset, aged ≥ 18 years, medically stable as deemed by their physicians, able to walk at least 5 meters with/without gait aid and with ongoing walking or balance goals. Demographic and stroke characteristics, including stroke risk factors, infarct location and volume, leukoaraiosis on routine MRI, and acute stroke treatments (e.g., thrombectomy) will be determined and documented. A battery of impairment, psychosocial, and functional measures, including the mRS and Timed-Up and Go test (primary outcomes) will be completed. Subsequently, participants will be set up to wear activPAL accelerometer, validated in stroke, for 1 week. Following randomization, a sedentary behaviour change intervention will span 6 weeks, with final follow-up assessments at 90 days.
Recruiting1 award N/A5 criteria
More about Brian H. Buck, MD, FRCPC
Clinical Trial Related1 year of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Brian H. Buck, MD, FRCPC has experience with
- Tenecteplase
- Aspirin
- Clopidogrel
- Edoxaban 30 Mg
- Edoxaban 60 MG
- Alteplase
Breakdown of trials Brian H. Buck, MD, FRCPC has run
Stroke
Bleeding
Atrial Fibrillation
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Brian H. Buck, MD, FRCPC specialize in?
Brian H. Buck, MD, FRCPC focuses on Stroke and Bleeding. In particular, much of their work with Stroke has involved treating patients, or patients who are undergoing treatment.
Is Brian H. Buck, MD, FRCPC currently recruiting for clinical trials?
Yes, Brian H. Buck, MD, FRCPC is currently recruiting for 3 clinical trials in Edmonton Alberta. If you're interested in participating, you should apply.
Are there any treatments that Brian H. Buck, MD, FRCPC has studied deeply?
Yes, Brian H. Buck, MD, FRCPC has studied treatments such as Tenecteplase, Aspirin, Clopidogrel.
What is the best way to schedule an appointment with Brian H. Buck, MD, FRCPC?
Apply for one of the trials that Brian H. Buck, MD, FRCPC is conducting.
What is the office address of Brian H. Buck, MD, FRCPC?
The office of Brian H. Buck, MD, FRCPC is located at: University of Alberta, Edmonton, Alberta T6G2B7 Canada. This is the address for their practice at the University of Alberta.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.